NCT03422757

Brief Summary

This is an exploratory study to preliminary assess safety and efficacy of an adaptive Deep Brain Stimulation (DBS) closed-loop method in patients with PD. The study has been designed as a double blind randomized crossover trial that uses conventional DBS as a concurrent control in PD patients in need of Implantable Pulse Generator (IPG) replacement.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable parkinson-disease

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

4 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2017

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 15, 2017

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 6, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2018

Completed
Last Updated

November 19, 2020

Status Verified

November 1, 2020

Enrollment Period

1.6 years

First QC Date

December 15, 2017

Last Update Submit

November 17, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total Electrical Energy Delivered (TEED) to the patient

    Difference in the TEED delivered to the patient in adaptive DBS versus conventional DBS mode.

    One day.

Secondary Outcomes (3)

  • Incidence of device related Adverse Events (safety and tolerability)

    One day.

  • Unified Parkinson's Disease Rating Scale (UPDRS) part III

    One day.

  • Unified Dyskinesia Rating Scale (UDysRS)

    One day.

Other Outcomes (5)

  • Time "off"

    One day.

  • DBS Impairment Scale (DBS-IS)

    One day.

  • Local field potentials (LFP) during gait analysis

    Four hours.

  • +2 more other outcomes

Study Arms (2)

adaptive DBS

EXPERIMENTAL

adaptive Deep Brain Stimulation, by AlphaDBSvext.

Device: adaptive Deep Brain Stimulation

conventional DBS

ACTIVE COMPARATOR

conventional Deep Brain Stimulation, by AlphaDBSvext.

Device: conventional Deep Brain Stimulation

Interventions

The investigational medical device ("AlphaDBSvext") is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD. In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal.

adaptive DBS

The same investigational medical device ("AlphaDBSvext") is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation.

conventional DBS

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of idiopathic PD;
  • DBS implant since at least 3 years and in need of battery replacement, defined by battery level \<25%;
  • Patients must be able to sign the informed consent document to participate in the clinical trial;
  • Patients with a suboptimal response to DBS treatment.

You may not qualify if:

  • Patients with severe cognitive decline (MMSE \<25);
  • Patients with major psychiatric issues;
  • Patients with any medical condition potentially interfering with DBS battery replacement surgery;
  • Patients that cannot tolerate an interruption of DBS stimulation;
  • Patients taking only one levodopa dose per day;
  • Patients with no LFPs recorded from any contacts pair, during intraoperatory IPG replacement procedure;
  • Pregnant or breastfeeding women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Centro Parkinson e Disturbi del Movimento ASST G.Pini- CTO

Milan, Italy

Location

Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico

Milan, Italy

Location

IRCCS Istituto Ortopedico Galeazzi

Milan, Italy

Location

Fondazione Istituto Neurologico Nazionale Casimiro Mondino

Pavia, Italy

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2017

First Posted

February 6, 2018

Study Start

June 1, 2017

Primary Completion

December 30, 2018

Study Completion

December 30, 2018

Last Updated

November 19, 2020

Record last verified: 2020-11

Locations